A METHOD AND APPARATUS FOR TREATMENT OF DRUG RESISTANT HYPERTENSION ASSOCIATED WITH IMPAIRED LEFT VENTRICULAR FUNCTION AND BRADYCARDIA USING A CARDIAC PACEMAKER

Abstract

The illustrated embodiments include an apparatus having a programmable, implantable pacemaker with a controllable pacing rate; and a blood pressure monitoring device having an output communicated to the pacemaker. The pacemaker selectively and automatically modulates pacing rate in response to monitored blood pressure to reduce hypertensive blood pressure in a patient or treatment for DCHF (HPpEF). The embodiments also include a. method tor operating a pacing device to treat drug resistant hypertension which includes the steps of monitoring blood pressure; and controlling rate modulation in the pacing device in response to the monitored blood pressure to selectively prevent excessive pacing to reduce mean arterial blood pressure fay either inhibiting rate modulation in the pacing device or by changing rate modulation parameters.

Claims

1.-8. (cancelled)

9. A method for operating a pacing device comprising: activating a systolic blood pressure monitor coupled to a patient; storing a number of systolic blood pressure readings; determining a baseline systolic blood pressure reading; selecting the following parameters for use in a pacemaker for blood pressure regulation, namely a target SBP (systolic blood pressure), a lower limit of acceptable SBP; a target treatment interval in minutes; and/or target pacing rate change per treatment interval at a predetermined pacing rate change percentage; monitoring systolic blood pressure; if systolic blood pressure exceeds the target SBP, using a pacemaker having a pacing rate to treat the patient by: increasing the pacing rate of the pacemaker by either a default level of 5% per treatment, or by a different predetermined value; monitoring the SBP for a predetermined time period to establish the new blood pressure baseline; comparing SBP to a preselected optimal SBP; increasing the pacing rate of the pacemaker by a predetermined incremental amount; and repeating the steps of comparing SBP and increasing the pacing rate of the pacemaker until either the SBP falls to the target SBP, or the pacing rate of the pacemaker exceeds a predetermined maximal value.

10. The method of claim 9 where the pacing rate of the pacemaker Is a RA pacing rate.

11. The method of claim 9 where monitoring blood pressure comprises monitoring peripheral blood pressure, intravascular blood pressure or intracardiac blood pressure.

12. The method of claim 11 where monitoring peripheral blood pressure comprises monitoring peripheral blood pressure with a pneumatic device, a non-pneumatic device or an implantable device implanted within a blood vessel or a heart chamber.

13. The method of claim 9 further comprising monitoring blood oxygen levels, glucose levels, blood electrolytes levels or other blood parameters and controlling the pacing rate in response to the monitored blood oxygen levels, glucose levels, blood electrolytes levels or other blood parameters.

14. The method of claim 9: where the pacing device is a RA pacemaker, where selecting the following parameters for use in a pacemaker for blood pressure regulation includes selecting a percentage of time paced in the RA to auto-adjust pacing rate changes at determined minimal and maximal increments, and a maximal paced HR limit established for each patient, not to be exceeded by the pacing device irrespective of BP changes; where if systolic blood pressure exceeds the target SBP, using a pacemaker having a RA pacing rate to treat the patient where treating the patient alters blood pressure by increasing the RA pacing rate of the pacemaker by either a default level of 5% per treatment, or by a different predetermined value, where increasing the pacing rate of the pacemaker by a predetermined incremental amount increases the RA pacing rate; and where repeating the steps compares SBP and increases the RA pacing rate of the pacemaker until either the SBP falls to the target, SBP, or the RA pacing rate of the pacemaker exceeds a predetermined maximal value.

15. A method for operating a pacing device comprising: monitoring blood pressure; and controlling rate modulation in the pacing device in response to the monitored blood pressure to selectively prevent excessive pacing to reduce mean arterial blood pressure by either inhibiting rate modulation in the pacing device or by changing a rate modulation parameter.

16. The method of claim 15 where changing rate modulation parameters comprises changing acceleration of pacing rate including magnitude of acceleration, and/or duration of acceleration, and changing deceleration of pacing rate including magnitude of deceleration, and/or duration of deceleration.

17. The method of claim 15 where monitoring blood pressure monitors systolic blood pressure; and where controlling rate modulation in the pacing device in response to the monitored blood pressure controls rate modulation in the pacing device in response to the monitored systolic blood pressure to selectively prevent excessive pacing to reduce mean systolic arterial blood pressure by either inhibiting rate modulation in the peeing device or by changing rate modulation parameters.

18. The method of claim 15 where monitoring blood pressure includes monitoring diastolic blood pressure; and where controlling rate modulation in the pacing device in response to the monitored blood pressure includes controlling rate modulation in the pacing device in response to the monitored diastolic blood pressure to selectively prevent excessive pacing to reduce mean diastolic arterial blood pressure by either inhibiting rate modulation m tile pacing device or by charging rate modulation parameters.

19. The method of claim 15 further comprising monitoring blood oxygen levels, glucose levels, blood electrolytes levels or other blood parameters arid controlling the pacing rate in response to the monitored blood oxygen levels, glucose levels, blood electrolytes levels or other blood parameters.

20. The method of claim 15 where monitoring blood pressure comprises monitoring peripheral blood pressure, intravascular blood pressure or intracardiac blood pressure.

21. The method of claim 15 where the rate modulation takes the form of natural pacing throughout an entire daily cycle with a heartbeat induced by each pacing stimulus at a rate in response to monitoring blood pressure without reference to respiration.

22. The method of claim 15 further comprising using monitoring blood pressure and controlling rate modulation to treat patients with drug-resistant, heart failure with preserved ejection fraction (HFePF).

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0069] FIG. 1 is diagram illustrating the programming of the pacemaker with the blood pressure monitor using an external programming device.

[0070] FIG. 2 is a flow diagram of the programming steps used in the diagram of FIG. 1.

[0071] FIG. 3 is flow diagram of the programming of the communication of the blood pressure monitor with the pacemaker.

[0072] FIG. 4 is a diagram of the feedback control of the treatment algorithm of one of the illustrated embodiments.

[0073] FIG. 5 is a flow diagram showing the monitor-only mode of operation.

[0074] FIG. 6 is a flow diagram of an embodiment of the treatment algorithm.

[0075] The disclosure and its various embodiments can now be beter understood by turning to the following detailed description of the preferred embodiments which are presented as illustrated examples of the embodiments defined in the claims. It is expressly understood that the embodiments as defined by the, claims may be broader than die illustrated embodiments described below.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0076] H>pertension increases incrementally with aging. Heart Rate incrementally decreases with aging. While, multiple factors combine to cause hypertension to develop and progress with aging, including but not limited to atherosclerosis, decreased elasticity of arteries., do increased ‘stiffness’

[0077] ami progressive renal insufficiency, an argument can be made that bradycardia is another heretofore unrecognized important factor, one for which a new treatment option is available that will slow or prevent the progression of simple hypertension to the drug resistant variety and ultimately diastolic heart failure. Aging causes a drop in the heart rate, which is called sino atrial node dysfunction (SAND). SAND activates the sympathetic nervous system to increase peripheral vascular resistance according to the fluidic law below, The basic tenet of hemodynamics is that total blood flow is equal to «hiving pressure divided by resistance. This can be expressed in the same manner as Ohm's Law of electricity.

ΔP=Q R

[0078] where R is resistance to flow, ΔP is the change in pressure across the circulation loop (systemic/pulmonary) from Its beginning (immediately after exiting the left ventricle/right” ventricle) to its end (entering the right atrium/left atrium), and Q is the flow through the vasculature (when discussing systemic vascular resistance (SVR) this is lequal to cardiac, output). This is the hydraulic version of Ohm's law, V=lR (which can he restated as R=), in which the pressure differential is analogous to the electrical voltage drop, flow is analogous to electric current, and vascular resistance Is analogous to electrical resistance. In some embodiments the algorithm processes SVR instead of SRP, DBF, or mean AP. The math is different, but the logic and functionality is essentially the same.

[0079] Consider first the nature of pathophysiology. If heart rate falls, mean arterial blood pressure can be maintained by increasing stroke volume (SV), which is a known compensatory mechanism of the healthy heart. However, when the left ventricle is impaired for a variety of reasons, such as prior heart attacks, hyper ensive enlargement, primary muscle disease, or in the presence of significant valvar heart disease, and for other reasons, and HR also tails, R must increase to maintain blood pressure.

[0080] It follows, therefore, “that the combination of both bradycardia (HR too low) and impaired SV would lead to increased R which would then lead to clinical hypertension and ultimately hypertensive heart failure when cardiac output is inadequate to overcome excess peripheral resistance.

[0081] It also follows that, in a patient with elevated R (significant hypertension) due to both reduced HR and SV, increasing HR, such as through the action of a pacemaker, would reduce Rand thereby reduce the need for medication. Lowering R by this means should also result in a lower incidence of hypertension-induced heart failure.

[0082] If the heart tails, blood Sow to the body's tissues must be maintained by a combination of increased left ventricular stroke volume (LVSV) and pulse rate {PR}, A combination of aging, left ventricular hypertrophy due to hypertension, and other factors such as atherosclerosis progressively impair left ventricular performance which further demands an increase in PR. This negative feedback loop is worsened by increasing LV hypertrophy stimulated by increased LV work against high PR. Diastolic heart failure occurs when the higher filling pressure required by the stiff and hypertrophied left ventricular causes back up of blood into the lungs, This results in the classic clinical presentation of DCHF, which includes shortness of breath* fatigue, and peripheral edema, As the rigid and left atria stretch due to the effect of higher ventricular filling pressures, a compensatory mechanism is triggered within the atrial tissues to reduce PR and intravascular volume. Although it is not currently clearly understood, we believe that this compensatory mechanism includes the release of atrial naturetic peptides.

[0083] Turn Row to clinical data supporting relevant to the illustrated embodiments of the invention. We studied retrospectively thirty patients satisfying the standard criteria for permanent; pacemaker implant based upon bradycardia (sinus node dysfunction) who also had dreg resistant hypertension. We hypothesized that if the above argument is true, the pattern's hypertension post pacemaker implant should be lessened as manifested by tower blood pressure readings compared to pre-implant levels, and the need for hypertension medication lessened.

[0084] Thirty elderly patients (n−30) with impaired SV bradycardia (sinoatrial node dysfunction,) who also had drug resistant hypertension CHTN defined as the chronic use of at least four HTN agents from different drag classes not including a beta adrenergic blocking agent and who satisfied Class 1A criteria for permanent pacemaker implantation were studied before and after pacemaker incantation. A significant change in HTN management was defined as a drop of 15 mmHg systolic. or 10 mmHg diastolic an multiple readings over at least three months after pacemaker implant, and/or the deletion at least one anti-HTN agent without concomitant increase in the dosage of any other agent durring the same period of time,

[0085] Six months after pacemaker implant 23 of 30 patients (77%, p<, O.05) showed a significant improvement in HTN, 18 patients had a significant decrease in systolic pressure, 9 patients a significant decrease in both in both systolic and diastolic blood pressure, and 18 patients a change in drug usage: 19 patients dropped at least one anthypertensive drug, 12 patients dropped two drags, and 2 patients dropped three drags. The average onset of this effect was observed i+/. 0,6 months after pacemaker implant.

[0086] The data proves that, in elderly patients with the combination of impaired stroke, sinus node dysfunction satisfying AHA criteria for pacemaker implant, and drug resistant HTN. pacemaker implant may significantly improve HTN, and hypertension management. The impaired stroke volume of these patients was presumed volume based upon left ventricular hypertrophy and diastolic dysfunction which is impaired LV relaxation. Pacemaker implant should also improve the long-term outcomes of patients with significant drag resistant HTN and concomitant sinus node dysfunction fey reducing not only the need for complex drug regimens, but also the development of the complications of drug resistant hypertension, including diastolic heart failure, kidney disease, and stroke,

[0087] The disclosed software should be added to AICD'S which are not primary pacing devices and lack an RA lead when the patient has heart failure but not enough bradycardia to qualify for a pacemaker. This would result in single chamber ICDs being dropped in favor of dual chamber ICDs exclusively in patients with DRH and DRH with DCFIF. While this is an attractive hypothesis, we currently have no clinical data on this group of patients (with systolic heart failure) and permanent pacing. The primary goal of pharmacological therapy in heart failure is to reduce R, Because such patients have a high incidence of the later development of stmts node dysfunction (Bigger JT Jr, Reiffel JA. Sick sinus syndrome. Anm Rev Med. 1979;30:91-118.) and are often administered drug that suppress heart rate as a side effect of therapy, such as beta adrenergic blocking drugs, an argument can be made to implant a device that combines both an AICD and dual chamber function (with a third lead or CRT-D as appropriate) as the first device.

[0088] For the purpose of this application, bradycardia is defined as a mean heart rate sustained: less than 60 beats per minute; chronotropic incompetence is defined as when HR fails to reach an arbitrary percentage (either 85%, 89%, or less commonly, 70%) of the age predicted maximal HR (usually based the “220—age” equation) obtained during an incremental dynamic exercise test. We focused on patients with DRH and DRH with DCHF and found an improvement in DRH in terms of the number of drags needed, actual lowering of SBP in both studies and DBF too in the other, and a reduction in hospitalizations for heart failure,

[0089] It can now be appreciated that the embodiments of the invention include various kinds of blood pressure sensing devices, such as non-invasive devices like cuffless wrist-type (non-pneumatic wave form analysis), cuff type arm or leg devices, cuffless waveform devices for BP analysis on any region of the body where arterial pulse can be sensed, e.g. using optical, plethysimoga phic, thermographic, electrical impedance, or electromagnetic means. Also included are invasive devices implanted in blood vessel outside the heart or implanted inside the heart.

[0090] The controlling software may be located in the blood pressure sensing device which then sends signal to pacemaker, in a peripheral device, but not the blood pressure sensor or the pacemaker, namely in a smart phone or computer, a conventional medical office «-programmer, an iPad (near the- patient or a remote site), or in the pacemaker. The software is based on either manual input or is automatic. Control signals are generated based on measured systolic or diastolic BP, or mean blood pressure. The control signals are used to adjust right atrial pacing, up or down although the scope of the invention also extends to RV and LV pacing,

[0091] The pacemakers which are employed to implement the pacing control include atrial pacemakers (atrioventricular Conduction intact, lead in RA), dual chamber pacemakers (atrioventricular conduction not intact, leads, in RA and RV), Pi-ventricular pacemakers cased in systolic heart Mure where intraventricular conduction is prolonged), also known as a CRT, dual chamber AICD, (essentially a dual chamber pacemaker with a shacking lead in RV), and CRT-D, (a In-ventricular pacemaker with a shocking lead in RV),

[0092] Consider three embodiments. The simplest or most primitive example is an open loop, manually controlled system. It is employed as a medical office procedure, uses a standard pneumatic blood pressure cuff, a doctor's office pacemaker programmer near the patient, and a conventional normally programmable dual chamber pacemaker. The patient sits near doctor. Blood pressure is taken with standard pneumatic cuff. The physician looks sfor systolic blood pressure on a printed table displaying the disclosed algorithm in a tabular format and determines an optimum RA pacing rate. The physician places a pacemaker programmer wand (RF source) over tht patient's pacemaker and uses the programmer o reprogram the pacemaker to desired >RA pacing rate according to the teachings of the disclosed embodiments.

[0093] The next preferred «Mboilli t is configured as a closed loop, automatic system. A etiffless wrist-type blood pressure sensor with wireless connectivity is used and a smart phone app with disclosed algorithm receives blood pressure readings. The BP reading is encrypted and sent to the pacemaker wirelessly, The pacemaker receives the encrypted blood pressure reading, authenticates, and alters R A pacing rate,

[0094] The third embodiment is a home monitoring and remote processing system. All front-iiiie pacemakers offer home monitoring. The patient is given a device that is commonly left at the bedside. When the, patient moves near it, such as going to bed, tire device wirelessly interrogates the pacemaker, monitoring such things as battery voltage and recent arrhythmia activity, and sends it via the phone fines in encrypted form to a remote central station operated by the pacemaker company. inbound instructions are sent by the same system to alter the pacemaker's programming and/or alert the treating physician that adverse events have occurred, such as arrhythmias or device dysfunction.

[0095] in additional ones of the illustrated embodiments all different types of pacemakers, e.g. AP, DCiy D

[0096] C AIC), CRT, or CRT-D, were operated, or used tor a wide permutation of cardiac symptoms or abnormalities, for example for the indicated combinations: [0097] DRH+B+ISV-S [0098] DRH+B+ISV-D [0099] DRH+CI+ISV-S [0100] DRH+CI+ISV-D [0101] DRH+B [0102] DRH+CI [0103] DRH+CI [0104] DRH+DHF+B (This adds the variable of DHF also being present) [0105] DRH+DHF+CI [0106] DRH+SHF+B (This adds the variable of SHF also being present.) [0107] DRH+SHF+CI

[0108] Where: DRH=Drug Resistant Hypertension; B=Bradycardia defined as a persistent HR<60 (higher than the Guidelines); CI=chronotropic incompetence as defined above; ISV-S=impaired Stroke Volume due to failure of systolic function: ISV-D Impaired Stroke Volume due to failure of diastolic function: DHF=diastolic-heart failure or heart failure with a preserved LV function (LVEF>50%). This is another form of ISV where the Left Ventricle contracts normally, but relaxes in an impaired manner; SHF=systolic heart failure or heart failure with reduced LV function (LVEF<35%);

[0109] The illustrated embodiments of the invention were also directed to methods of operating or using a pacemaker to treat heart failure {systolic and diastolic} by reducing peripheral resistance (It) with or without the presence of sinus node dysfunction. The current guidelines for the implantation of a permanent pacemaker in the presence of sinus node dysfunction are too strict in patients who also have heart failure. Many heart failure patients have lower than effective heart rates (relative bradycardia) and both with and without high resistance, but do not satisfy the very strict current AHA Guidelines for pacemaker implant. The presence of relative bradycardia sufficient to increase peripheral resistance (the primary therapeutic point of attack for nort-surgical heart failure therapy) and heart failure should be sufficient to warrant pacemaker implant. This would include patients with relative bradycardia and lesser chronotropic incompetence not currently meeting the AHA Guidelines for pacemaker implant.

[0110] The magnitude of the diminished capacity to respond to Bradycardia is proportional to LV function. The lower the LV function, the more profound is the effect of bradycardia on peripheral resistance, which is manifest as elevated blood pressure, and peripheral resistance is the major determinant of morbidity and mortality in heart failure. Therefore, the criteria for pacemaker implant in patients who have DRH and DRH with DC.H.F, and all forms of CHF and relative bradycardia should not be limited by the current AHA Guidelines, This increases the cohort of patients who should have atrioventricular pacing to include all patients with heart failure and relative bradycardia. While relative bradycardia is defined the purposes of this embodiment as either the presence of chronotropic incompetence or a HR less than 60 and greater than 40, it is to be expressly understood that this definition cap fee modified as determined by later clinical trials of the pacing methodology without departing from the scope of the invention.

[0111] Thus, the illustrated embodiments of the invention are directed to a method of operating or using an implantable pacemaker (AP, DCP, CRT, CRT-D) to treat diastolic heart failure in patients with concomitant bradycardia relative or meeting the AHA guidelines, concomitant chronotropic incompetence and/or chronotropic incompetence with drag resistant hypertension to optimize peripheral resistance by the restoration of a normal heart rate. These methods of operation and use of implanted pacemakers are based upon utilizing a pacing therapy to reduce peripheral resistance as means of treatment of at least some types of heart failure, Reducing peripheral resistance is the primary goal of nonsurgical heart failure treatment, Surgical treatment Includes bypass surgery, heart transplantation, and implantation of heart assist devices.

[0112] Therefore, it can be appreciated that the operation and use of implanted pacemakers treat heart failure is the primary end point of the pacing operation or use. The endpoints of treatment are both heart failure and concomitant drug resistant hypertension, in each permutation of systems what is indicated is the use and operation of all type* of pacemakers, for example including in such diagnostic permutations as: DBF 4-CI; DHF+B; SHF 4-B; and SHF+CI as well as in the treatment of heart failure with concomitant drug resistant hypertension including in such diagnostic permutations as: SHF+B+DKH; SHF=CI+DRH; DBF+B+DRH; and DHF+CI 4 DRH.

[0113] Consider an embodiment or the iavention wherein it is realized in a scenario as shown in FIG. 1 with an external programming devicei 10 and a wristwatch type blood pressure monitor 12. The patient is fitted with a pacemaker 14 connected to the patient's heart 16 with the blood pressure modulation software resident in the pacemaker's processor. The patient is also fitted the blood pressure monitor 12 mounted in a wristwatch band with encrypted blue tooth connectivity linking it uniquely to the patient's pacemaker 14. The patient or clinician activates wristwatch blood pressure monitor 12 and selects the number of blood pressure readings to store, and how far apart in minutes the measurements are separated. This data set comprises the baseline blood pressure readings of the illustrated embodiment of the invention, The BP measurements are carried out according to the predetermined schedule and the data set, the baseline blood pressure readings, is created and stored in the pacemaker 14. Using the external programming device 10, the clinician pairs the patient's wristwatch blood pressure monitor 12 to the pacemaker 14 by entering the unique serial numbers of the pacemaker 14 and the blood pressure monitor 12 allowing blue tooth encrypted interconnectivity of both devices, if the blood pressure monitor 12 is inactivated for any reason, the blood pressure algorithm in the pacemaker 14 becomes dormant ami the pacemaker 14 returns to regular function unmodulated by the external blood pressure readings or the internal blood pressure modulation algorithm.

[0114] The clinician inputs the following parameters through the external programming device 10. which parameters are transmitted to the pacemaker 14 and integrated into the blood pressure regulating algorithm, The clinician inputs a desired SBP (systolic blood pressure) and inputs a lower limit of acceptable SBP, For example, the desired treatment interval in minutes and a desired RA pacing change per treatment interval from 0-40% is input. After the clinician directed software functions are programmed, the external programming device 10 is inactivated and the patient's pacemaker 14 paired with the wearable blood pressure monitor 12 begins automatic functioning. The flow diagram of FIG. 2 summarizes this initial programming session. At step 18 the clinician logs onto the external programming device 10 to gain access to the pacemaker 14 and BP monitor 12. He or she enters the serial number of patient's wearable blood pressure monitor 12 at step 20. The pacemaker 14 will now only accept data from the designated BP monitor 12. The clinician downloads into the external programming device 10 the baseline BP data set from the patient's BP monitor 12 at step 22. The clinician uses that data set to program the treatment algorithm by setting at step 24: the target SBP; maximal SBP; minimum SBP; selected time between monitor intervals, which may be preset at ten minutes; selected, time between RA pacing adjustments, which may be preset at ten minutes; and percentage RA pacing change per treatment interval, which may be preset at 5%. The instructions are encrypted and sent to the pacemaker 14 at step 26.

[0115] As shown in the flow diagram of FIG. 3 the blood pressure monitor 12 and the patient's pacemaker 14 are paired using encrypted blue tooth technology. The patient activates the wearable BP monitor's 12 encrypted; blue tooth link to the pacemaker 14 at step 28. BP monitor 12 sends a test signal to pacemaker 14 as step 30 to validate pairing and integrity of the signal. The monitor 12 notifies the patient that encrypted pairing is complete at step 32, BP monitor 12 measures the BP. The BP data is encrypted and communicated to the external programming device 10 and to the pacemaker 14 at step 34. The external programming device 10 decrypts the data and displays it at step 36, Selective treatment by pacemaker 14 is then activated through the external programming, device 10 at stop 38.

[0116] While the patient carries on ordinary activities, the software in the pacemaker 14 processes the blood pressure data transmitted by the blood pressure monitor 12 and establishes: 1) the steady state BP, namely the average blood pressure based upon recent blood pressure readings; and 2) the steady state RA pacing, namely the average right atrial pacing rate during the same time intervals.

[0117] If the average systolic blood pressure, namely most recent steady-state readings, exceeds the preprogrammed limits set by the clinician, treatment is automatically initiated. If the most recent steady state readings are below the treatment plateau programmed by the clinician, the software does not alter the right atrial pacing rate and no blood pressure treatment is delivered, if a decision to treat has been made by the software, the RA pacing rate is increased by either the default level of 5% per treatment, or by a different value pre-programmed by the clinician using the external programming device 10. For example one possible treatment option would be to increase RA pacing 7%

[0118] The SBP is monitored for twenty minutes, or for a different time interval preprogrammed by the clinician, to establish the new blood pressure baseline. If the SBP is still above the clinician's pre-selected optimal SBP, the treatment is repeated by increasing the RA pacing rate another 5% or by a different amount as pre-programmed by the clinician. This cycle of monitoring and selective treatment is repeated until either the SBP tolls to the pre-programmed optima! level, or the RA pacing rate exceeds 40% or a different maximal value pre-programmed by the clinician.

[0119] FIG. 4 illustrates the selective treatment in a rate modulation mode. The blood pressure monitor 12, the blood pressure modulating software 40, and the pacemaker 14 form an automatic feedback loop to regulate pacemaker function, which in this embodiment is RA pacing but need not be so limited, to lower blood pressure. The algorithm utilizes the -following parameters to determine or modulate the optimal RA pacing percentage to optimize BP: [0120] 1) Blood pressure input, both systolic and diastolic, from an external blood pressure monitor 12, [0121] 2) RA pacing percentage [0122] 3) Instantaneous heart rate [0123] 4) Maximal preset RA pacing percentage, which is set at 40% unless overridden fay further data collection or the clinician, [0124] 5) Desired maximum blood pressure, most likely systolic. Insufficient data exists at this time to determine the relationship between diastolic BP and RA pacing, [0125] 6) Desired minimum blood pressure. [0126] 7) Sampling time between blood pressure measurements, namely the interval increase or decrease in RA pacing during each treatment interval, [0127] 8) The number of BP measurements necessary to calculate steady stale BP [0128] 9) The time between BP measurements to calculate steady state BP [0129] 10) The time in minutes between treatment intervals.

[0130] The treatment algorithm In the rate modulation mode relates the instantaneous change in SBP with the change in RA pacing percentage, such that the drop in SBP is mapped to an increase in RA pacing times a constant A+constant B.

Δ SBP=(& RA)A 4-B

[0131] In the present embodiment based upon currently available clinical data, which may be later refined by subsequent data gathered, A≈−0.31, and B=16. In the currently preferred embodiment of the treatment algorithm the change in SBP and RA pacing are expressed as a percentage.

[0132] FIG. 5 is a low diagram which illustrates further processing undertaken in pacemaker 14. At step 42 steady state BP is inpat, either baseline BP if it is the first use, the BP during the last ten minutes, or such time as otherwise programmed by clinician. At step 44 access steady state RA pacing, either baseline if it is a first use, the rate during the last ten minutes, or at such time otherwise as programmed by clinician, if the software is in monitor-only mode as determined at step 46, either because it .has beer* disabled or the desired blood pressure has been detected in steady state, the RA pacing rate is set at step 48 by the clinician at a selected lower rate limit. Otherwise pacemaker 14 is or will continue to operate in the rate modulation mode.

[0133] When the patient exercises, or the pacemakers rate modulation software is activated for any reason, BP will be affected and RA pacing will rise. The algorithm will default to monitor-only mode so long as the increase in RA pacing does not drop the blood pressure below the preset minimum SBP. If the SBP drops below the preset minimum, the rate modulation mode will be inhibited. This is a new pacemaker safeguard for all devices across all brands that offer rate modulation software as feature of their pacemakers. It will protect the patient from an excessive drop in SBP caused by excessive RA pacing, or dual chamber pacing such as RAIRV or RAIL V.

[0134] The apparatus and a method operate a pacing device 14 as depicted diagrammatically in the flow diagram of FIG. 6 by including the steps of: [0135] 1) activating a wristwatch blood pressure sensor 12 at step 50; [0136] 2) storing a number of blood pressure readings, temporarily separated in a predetermined pattern, to establish a baseline blood pressure- reading at step 52; [0137] 3) selecting at step 54 the following parameters for use in the right atrial pacemaker for blood pressure regulation; [0138] i. desired SBF (systolic blood pressure); [0139] ii. lower limit of acceptable SBP: [0140] iii. desired treatment interval in minutes; and/or [0141] iv . desired RA pacing change per treatment interval where for example the change ranges from 0-40% or such other predetermined percentage range consistent with the teachings of this invention; [0142] 4) monitoring blood pressure at step 56 and if blood exceeds the desired SBP as determined at step 58, using the pacemaker 14 to treat the patient at step 60 by: [0143] i. increasing the RA pacing rate by either a default level of 5% per treatment, or by a different predetermined value; [0144] ii. monitoring the SBP for a predetermined time period to establish the new blood pressure baseline: [0145] iii. comparing SBP to a pre-selected optima! SBP; [0146] iv. increasing the RA pacing rate by a predetermined Incremental amount; and [0147] v. repeating the steps of comparing SBP and increasing RA pacing rate until either the SBP fells to the target or pre-programmed optimal level, or the RA pacing .rate exceeds a predetermined maximal value as depicted at step 62,

[0148] Tbs algorithm and methods of utilization herein described also significantly improve existing pacemaker heart rate modulating programs by optimizing if A pacing in response to blood pressure as well as exercise parameters. Exercise-induced syncope (fainting) or dizziness is a well-recognized clinical phenomenon. When a patient with a pacemaker exercises, his/her heart rate will be regulated by the pacemaker's programmed rate modulation software if activated. According to the data herein presented, elevation of the patient's heart rate could also result in a lowering of blood pressure such that the patient might experience dizziness or syncope. By use of this methodology in the patient's pacemaker an excessive drop in blood pressure is prevented fey inhibition of the patient's pacemaker's rate modulation function.

[0149] Many alterations and modifications may fee made by those having ordinary skill in the art without departing from the spirit and scope of the embodiments. Therefore, it mast be understood that the illustrated embodiment has been set forth only for the purposes of example and that it should not be taken as limiting the embodiments as defined by the following embodiments and its various embodiments.

[0150] Therefore, it must be understood that the illustrated embodiment has been set forth only for the purposes of example and that It should not be taken as limiting the embodiments as defined by the following claims. For example, notwithstanding the fact that the elements of a claim are set forth below in a certain combination, it must be expressly understood that the embodiments includes other combinations of fewer, more or different elements, which are disclosed in above even when not initially claimed in such combinations. A teaching that two elements are combined in a claimed combination is further to be understood as also allowing for a claimed combination in which the two elements are not combined With each other, but may be used alone or combined in other combinations. The excision of any disclosed element of the embodiments is explicitly contemplated as within the scope of the embodiments.

[0151] The words used in this specification to describe the various embodiments are to be understood not only in the sense of their commonly defined meanings* but to include by special definition in this specification structure, material or acts beyond the scope of the commonly defined meanings. Thus if an element can be understood In the context of this specification as including more than one meaning, then its use in a claim must be understood as being generic to all possible meanings supported by the specification and fey the word itself.

[0152] The definitions of the words or elements of the following claims are, therefore, defined in this specification to include- not only the combination of elements which are literally set forth, but all equivalent structure, material or acts for performing substantially the same function in substantially the same way to obtain substantially foe same result. In this sense it is therefore contemplated that an equivalent substitution of two or more elements may be made for any one of the elements in the claims below; or that a single element may be substituted for two or more elements in a claim. Although elements maybe described above as acting in certain combinations and even initially claimed as such, it is to be expressly understood that one or more elements from a claimed combination can in some cases be excised from the combination and that the claimed combination may be directed to a subcombination or variation of a subcombination.

[0153] Insubstantial changes from the claimed subject matter as Viewed fey a person with ordinary skill In the art, now known or later devised, are expressly contemplated as being equivalently within the scope of the claims. Therefore, obvious substitutions now or later knows to one with ordinary skill in the art are defined to be within the scope of the defined elements.

[0154] The claims are thus to fee understood to include what is specifically illustrated and described above, what is conceptionally equivalent, what can be obviously substituted and also what essentially incorporates the essential idea of the embodiments.